PD-158780

N/A

Report date: 2026/05/13 20:02:10
NME

Base Information

Drug NamePD-158780
Drug Alias NamePD158780
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtein-tyrosine kinases inhibitorsEpidermal growth factor receptor erbB1 inhibitorsReceptor protein-tyrosine kinase erbB-4 inhibitors
TargetsProtein-tyrosine kinasesReceptor protein-tyrosine kinase erbB-4Epidermal growth factor receptor erbB1
Therapy Area/IndicationsAngelman SyndromeNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNew York UniversityPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNew York University
Active IndicationsN/A
Inactive IndicationsAngelman SyndromeNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A